600976.SHG Jianmin Pharmaceutical Group Co Ltd
- Market cap
- CNY 4.34B
- P/E
- 13.7x
- P/B
- 1.59x
- ROE
- 11.5%
- Dividend yield
- 3.18%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600976.SHG undervalued?
Graham number600976.SHG trades 1.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jianmin Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Jianmin Pharmaceutical Group Co Ltd yet.
Jianmin Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jianmin Pharmaceutical Group Co Ltd
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells traditional Chinese medicines and paediatric products in China. It provides over-the-counter, medical, and general health products in the form of capsules, granules, and gels under the Jianmin, Longmu, and Yekaitai brands. The company was founded in 1637 and is based in Wuhan, China.
Full company profileJianmin Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jianmin Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.36B | 2.71B | 2.16B | 2.24B | 2.46B | 3.30B | 3.64B | 4.21B | 3.50B | 3.35B | 3.06B |
| Gross Profit | 564M | 740M | 749M | 890M | 996M | 1.42B | 1.57B | 1.93B | 1.67B | 1.91B | 1.84B |
| Operating Income | 60.7M | 100M | 93.9M | 105M | 161M | 346M | 442M | 574M | 397M | 231M | 287M |
| EBITDA | 91.5M | 124M | 108M | 120M | 179M | 379M | 476M | 609M | 440M | 302M | 365M |
| Net Income | 64.7M | 90.8M | 81.2M | 91.5M | 148M | 305M | 408M | 521M | 362M | 360M | 318M |
| EPS | 0.42 | 0.59 | 0.53 | 0.60 | 0.96 | 2.01 | 2.68 | 3.41 | 2.38 | 2.35 | 2.07 |
| Balance Sheet | |||||||||||
| Total Assets | 1.81B | 1.92B | 1.72B | 1.93B | 2.42B | 2.83B | 3.44B | 4.17B | 4.28B | 4.53B | 4.54B |
| Total Liabilities | 776M | 817M | 577M | 721M | 1.09B | 1.26B | 1.57B | 1.91B | 1.83B | 1.81B | 1.76B |
| Shareholders' Equity | 1.01B | 1.09B | 1.14B | 1.20B | 1.32B | 1.56B | 1.86B | 2.25B | 2.44B | 2.66B | 2.76B |
| Cash & Short-term Investments | 248M | 181M | 82.8M | 476M | 577M | 837M | 861M | 1,000M | 1.12B | 1.20B | 218M |
| Total Debt | 9.67M | - | - | 52.2M | 20.0M | 57.0M | 53.3M | 110M | 169M | 292M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 114M | 35.2M | 63.6M | 74.4M | 126M | 259M | 216M | 268M | 234M | 275M | - |
| Capital Expenditure | 29.4M | 41.9M | 42.4M | 69.3M | 45.6M | 56.0M | 68.0M | 64.5M | 120M | 101M | 108M |
| Free Cash Flow | 84.4M | -6.74M | 21.2M | 5.13M | 80.0M | 203M | 148M | 204M | 114M | 174M | 279M |
| Ratios | |||||||||||
| ROE | 6.4% | 8.3% | 7.1% | 7.6% | 11.2% | 19.6% | 21.9% | 23.2% | 14.9% | 13.5% | 11.5% |
| ROA | 3.6% | 4.7% | 4.7% | 4.7% | 6.1% | 10.8% | 11.9% | 12.5% | 8.5% | 7.9% | 7.0% |
| Net Profit Margin | 2.7% | 3.3% | 3.8% | 4.1% | 6.0% | 9.3% | 11.2% | 12.4% | 10.3% | 10.7% | 10.4% |
| Debt to Equity | 0.01x | - | - | 0.04x | 0.02x | 0.04x | 0.03x | 0.05x | 0.07x | 0.11x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jianmin Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 3.18%
- Forward dividend
- 0.90 CNY
- Payout ratio
- 38.4%
- Ex-dividend date
- Apr 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 138M | 0.90 | 38.4% |
| 2024 | CNY 188M | 1.23 | 51.8% |
| 2023 | CNY 156M | 1.02 | 30.0% |
| 2022 | CNY 123M | 0.81 | 30.2% |
| 2021 | CNY 58.6M | 0.39 | 19.2% |
| 2020 | CNY 30.7M | 0.20 | 20.8% |
| 2019 | CNY 31.3M | 0.21 | 34.2% |
| 2018 | CNY 31.2M | 0.20 | 38.4% |
| 2017 | CNY 19.7M | 0.13 | 21.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jul 12, 2006.
Who owns Jianmin Pharmaceutical Group Co Ltd
- Insiders 33.60%
- Institutions 2.58%
- Public & others 63.82%
- Shares outstanding 153M
- Free float 109M
Jianmin Pharmaceutical Group Co Ltd company profile
- Company name
- Jianmin Pharmaceutical Group Co Ltd
- Ticker
- 600976.SHG
- ISIN
- CNE000001HB7
- Exchange
- Shanghai Stock Exchange
- Listed since
- Apr 2, 2004
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,257
- Fiscal year end
- December
- Address
- No. 484, Yingwu Avenue, Wuhan, China, 430052
- Phone
- 86 27 8452 3350
- Website
- whjm.com
About Jianmin Pharmaceutical Group Co Ltd
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells traditional Chinese medicines and paediatric products in China. It provides over-the-counter, medical, and general health products in the form of capsules, granules, and gels under the Jianmin, Longmu, and Yekaitai brands. The company was founded in 1637 and is based in Wuhan, China.
Jianmin Pharmaceutical Group Co Ltd management
7- Mr. Jun WangPresident & Director · born 1977
- Mr. Chaoyang ChengFinancial Director · born 1973
- Mr. Jie ZhouSecretary · born 1979
- Mr. Xuejun PeiVice President · born 1977
- Mr. Zhijun HuangVice President · born 1973
- Ying ZhangHead of Accounting & Accounting Supervisor
- Ms. Fangjing HuangDirector of Legal & Compliance Department · born 1987